An Overview of Specialist Services for Huntington's Disease in the United Kingdom.

Huntington’s disease NHS United Kingdom health services capacity health services organization

Journal

Journal of Huntington's disease
ISSN: 1879-6400
Titre abrégé: J Huntingtons Dis
Pays: Netherlands
ID NLM: 101589965

Informations de publication

Date de publication:
2023
Historique:
medline: 19 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: ppublish

Résumé

Huntington's disease (HD) is a rare inherited neurodegenerative disorder characterized by complex evolving needs that change as the condition progresses. There is limited understanding about the organization of HD clinical services and their resourcing in the United Kingdom (UK). To understand the organization and resourcing of specialist HD services for people with HD (PwHD) in the UKMethods:This cross-sectional study collected quantitative data via on online survey, and qualitative data via telephone semi-structured interviews. Descriptive statistics were used to describe quantitative outcomes, and qualitative results were analyzed using content analysis. A total of 31 specialist services for HD were identified. Of the 27 services that completed the online survey, 23 had an active multidisciplinary team of healthcare professionals (HCPs) and were led primarily by a mental health trust (26%) or tertiary referral hospital (26%). Specialist services offered outpatient clinics (96%), outreach in the community (74%), telemedicine (70%), inpatient beds (26%) and satellite clinics (26%). Many services indicated that their capacity (ability to see patients as often as needed with current resources) was difficult, with some services reporting more difficulty at the early or later stages of HD. Key resourcing gaps were identified with access to facilities, HCPs and referral networks. This research highlights the variation in organization and capacity within individual HD services as well as current resourcing and gaps in access that influence this capacity. Further research should be done to understand the impact of service organization and current resourcing gaps in access on the quality of care provided for PwHD in the UK.

Sections du résumé

BACKGROUND
Huntington's disease (HD) is a rare inherited neurodegenerative disorder characterized by complex evolving needs that change as the condition progresses. There is limited understanding about the organization of HD clinical services and their resourcing in the United Kingdom (UK).
OBJECTIVE
To understand the organization and resourcing of specialist HD services for people with HD (PwHD) in the UKMethods:This cross-sectional study collected quantitative data via on online survey, and qualitative data via telephone semi-structured interviews. Descriptive statistics were used to describe quantitative outcomes, and qualitative results were analyzed using content analysis.
RESULTS
A total of 31 specialist services for HD were identified. Of the 27 services that completed the online survey, 23 had an active multidisciplinary team of healthcare professionals (HCPs) and were led primarily by a mental health trust (26%) or tertiary referral hospital (26%). Specialist services offered outpatient clinics (96%), outreach in the community (74%), telemedicine (70%), inpatient beds (26%) and satellite clinics (26%). Many services indicated that their capacity (ability to see patients as often as needed with current resources) was difficult, with some services reporting more difficulty at the early or later stages of HD. Key resourcing gaps were identified with access to facilities, HCPs and referral networks.
CONCLUSIONS
This research highlights the variation in organization and capacity within individual HD services as well as current resourcing and gaps in access that influence this capacity. Further research should be done to understand the impact of service organization and current resourcing gaps in access on the quality of care provided for PwHD in the UK.

Identifiants

pubmed: 38108355
pii: JHD220560
doi: 10.3233/JHD-220560
pmc: PMC10741324
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

363-370

Subventions

Organisme : HCRW_
ID : HCRW_RFPPB-16A-1298
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom

Références

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1156-60
pubmed: 23482661
Cortex. 2019 Nov;120:353-374
pubmed: 31401402
J Huntingtons Dis. 2012;1(1):27-30
pubmed: 25063188
Int Rev Neurobiol. 2011;98:297-323
pubmed: 21907093
BMJ. 2010 Jun 30;340:c3109
pubmed: 20591965
Neurology. 2003 Mar 25;60(6):998-1001
pubmed: 12654967
Orphanet J Rare Dis. 2021 Feb 10;16(1):76
pubmed: 33568181
J Pers Med. 2022 Jan 07;12(1):
pubmed: 35055379
Neuroepidemiology. 2016;46(2):144-53
pubmed: 26824438
Int J Environ Res Public Health. 2018 Jun 01;15(6):
pubmed: 29865157
Front Neurol. 2019 Jul 03;10:710
pubmed: 31333565
J Huntingtons Dis. 2016 Jun 27;5(2):207-13
pubmed: 27372053
Brain Res Bull. 2007 Apr 30;72(2-3):175-8
pubmed: 17352943
Brain Sci. 2022 Jan 26;12(2):
pubmed: 35203927
Future Healthc J. 2018 Feb;5(1):64-80
pubmed: 31098535
Brain Res Bull. 2009 Oct 28;80(4-5):192-5
pubmed: 19576265
J Huntingtons Dis. 2017;6(3):217-235
pubmed: 28968244
Neurotherapeutics. 2014 Jan;11(1):153-60
pubmed: 24366610
Brain Sci. 2017 Jun 16;7(6):
pubmed: 28621715
Handb Clin Neurol. 2017;144:31-46
pubmed: 28947124

Auteurs

Rosa Willock (R)

HCD Economics, Cheshire, England, UK.

Hugh Rickards (H)

Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, England, UK.

Anne E Rosser (AE)

Schools of Medicine and Biosciences, Cardiff University, Cardiff, Wales, UK.

Alistair Haw (A)

Scottish Huntington's Association, Paisley, Scotland, UK.

Cath Stanley (C)

Huntington's Disease Association, Liverpool, England, UK.

Pushpa Hossain (P)

HCD Economics, Cheshire, England, UK.

Idaira Rodríguez-Santana (I)

HCD Economics, Cheshire, England, UK.

Maria Doherty (M)

HCD Economics, Cheshire, England, UK.

Rachel Blair (R)

Roche Products Ltd., Welwyn Garden City, England, UK.

Wendy Kane (W)

Roche Products Ltd., Welwyn Garden City, England, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH